menu
    • menu

    Company profile for Kymera Therapeutics

    NEW Drugs in Dev: 7
    Evonik

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    Contact Supplier

    End-to-end drug development, specializing in high-potency softgels and liquids, providing global partners with a competitive advantage.

    Virtual Booth

    Contact Supplier

    Kewpie is your partner for Sodium Hyaluronate & Hyaluronic Acid// CEP, USDMF, KDMF & JDMF registered.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Kymera Therapeutics is a biotechnology company pioneering a transformative new approach to treating previously untreatable diseases. The company is advancing the field of targeted protein degradation, accessing the body’s innate protein recycling machinery to degrade dysregulated, disease-causing proteins. Powered by Pegasus™, a game-changing integrated degradation platform, Kymera is accelerating drug discovery with an un...
    Kymera Therapeutics is a biotechnology company pioneering a transformative new approach to treating previously untreatable diseases. The company is advancing the field of targeted protein degradation, accessing the body’s innate protein recycling machinery to degrade dysregulated, disease-causing proteins. Powered by Pegasus™, a game-changing integrated degradation platform, Kymera is accelerating drug discovery with an unmatched ability to target and degrade the most intractable of proteins, and advance new treatment options for patients.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Kymera TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    200 Arsenal Yards Blvd., Suite 230 Watertown, MA 02472
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.kymeratx.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/kymeratherapeutics/
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/KymeraTx

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Tides Asia

    Tides Asia

    Not Confirmed

    envelop Contact Supplier

    Tides Asia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Kymera Therapeutics Outlines 2026 Immunology Strategy
    Kymera Therapeutics Outlines 2026 Immunology Strategy

    13 Jan 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/01/13/3217633/0/en/Kymera-Therapeutics-Outlines-Key-2026-Objectives-and-Strategy-to-Advance-Industry-Leading-Portfolio-of-Oral-Immunology-Programs.html

    GLOBENEWSWIRE
    13 Jan 2026
    Share Share
    Kymera Therapeutics To Present At J.P. Morgan Healthcare Conf
    Kymera Therapeutics To Present At J.P. Morgan Healthcare Conf

    06 Jan 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/01/06/3213474/0/en/Kymera-Therapeutics-to-Present-at-the-44th-Annual-J-P-Morgan-Healthcare-Conference-on-January-13.html

    GLOBENEWSWIRE
    06 Jan 2026
    Share Share
    Kymera Closes $602M Offering With Full Option Exercise
    Kymera Closes $602M Offering With Full Option Exercise

    11 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/11/3204288/0/en/Kymera-Therapeutics-Announces-Closing-of-Upsized-602-Million-Public-Offering-and-Full-Exercise-of-Underwriters-Option-to-Purchase-Additional-Shares.html

    GLOBENEWSWIRE
    11 Dec 2025
    Share Share
    FDA Grants Fast Track to Kymera's KT-621 for Atopic Dermatitis
    FDA Grants Fast Track to Kymera's KT-621 for Atopic Dermatitis

    11 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/11/3203770/0/en/Kymera-Therapeutics-Announces-U-S-FDA-Fast-Track-Designation-for-KT-621-a-First-in-Class-Oral-STAT6-Degrader-for-the-Treatment-of-Atopic-Dermatitis.html

    GLOBENEWSWIRE
    11 Dec 2025
    Share Share
    Kymera Therapeutics Announces Proposed Public Offering
    Kymera Therapeutics Announces Proposed Public Offering

    08 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/08/3201960/0/en/Kymera-Therapeutics-Announces-Proposed-Public-Offering.html

    GLOBENEWSWIRE
    08 Dec 2025
    Share Share
    Kymera Reports Positive Results In KT-621, Phase 1B Trial
    Kymera Reports Positive Results In KT-621, Phase 1B Trial

    08 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/08/3201397/0/en/Kymera-Therapeutics-Announces-Positive-Results-from-BroADen-Phase-1b-Clinical-Trial-of-KT-621-a-First-in-Class-Oral-STAT6-Degrader-in-Patients-with-Moderate-to-Severe-Atopic-Dermat.html

    GLOBENEWSWIRE
    08 Dec 2025
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search